ASCO GU Symposium 2023: Focus on Renal Cell Carcinoma
In-depth coverage of renal cell carcinoma research and clinical updates from the 2023 ASCO GU Symposium
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
Current categorization of pN1 can be subdivided into pN1 and pN2 based on a threshold hypothesized by researchers.
Researchers assessed TFS outcomes from HCRN GU16-260, investigating nivolumab and salvage nivolumab plus ipilimumab for aRCC.
Updated OS and efficacy results of second-line treatment in patients with mRCC treated in the BIONIKK trial were presented.
A survey shed light on current practice patterns for treatment selection and patient education for individuals with RCC.
Researchers presented the largest retrospective characterization of localized RCC with sarcomatoid dedifferentiation.
Latinx patients with mRCC demonstrated shorter PFS after nivolumab-plus-ipilimumab treatment at a tertiary care center.
A 24-month analysis highlighted OS, PFS, ORR, and best response to avelumab-plus-axitinib treatment in patients with aRCC.
Researchers compared the survival, efficacy, and safety features of second-line treatment regimens for mccRCC.
A research team sought to learn how patients and physicians trade off features of adjuvant RCC treatments.
Tian Zhang, MD, describes the current standard-of care treatment approach for metastatic RCC, including second-line therapy.
Matthew Zibelman, MD, highlights SOC adjuvant therapy for localized RCC and practice-changing potential of novel therapies.
Attendees will learn about different ways of managing renal cell carcinoma at all stages from research to practice.
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get conference updates straight to your inbox.
For Attendees
Get recommendations for sightseeing, dining, entertainment, and more while you're in town for the conference.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.